SCHEMBL699990

SCHEMBL699990

C=CCOc1ccccc1S(=O)(=O)[C@@H]1C[C@@H](C(=O)OCC)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 11/20 0.41
CTSL P07711 4/20 0.41
CTSB P07858 2/20 0.41
CTSK P43235 2/20 0.41
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NR1D1 P20393 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTRA1 Q92743 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
TGM2 P21980 2/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
F13A1 P00488 1/20 0.33
TGM1 P22735 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701022 0.89 CTSS (0.39) CTSSCTSLCTSBCTSKHTRA1
SCHEMBL2683231 0.83 CTSS (0.55) CTSSCTSLCTSBCTSKMEN1
SCHEMBL15327168 0.81 CTSS (0.58) CTSSCTSLCTSB
SCHEMBL696431 0.81 CTSS (0.58) CTSSCTSLCTSB
SCHEMBL697655 0.81 CTSS (0.38) CTSSCTSLCTSBCTSKGPR119
SCHEMBL15327167 0.81 CTSS (0.58) CTSSCTSLCTSB
SCHEMBL702381 0.81 CTSS (0.45) CTSSCTSLCTSBCTSKALDH1A1
SCHEMBL7729499 0.73 NR1H2 (0.35) MEN1KMT2AALDH1A1TGM2CYP1A2
SCHEMBL7729501 0.73 NR1H2 (0.35) MEN1KMT2AALDH1A1TGM2CYP1A2
SCHEMBL14974619 0.72 CTSS (0.53) CTSSCTSLCTSBCTSKNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CTSS 1542/4885CTSL 178/4885CTSB 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.